GENERIC DRUGS, FDA, AND INTELLECTUAL PROPERTY LAW

Joel E. Hoffman
Adjunct Professor of Law
Spring 2013
Syllabus


II. Summary Overview of FDA’s Product Approval Processes
   A. The New Drug Approval Process
   B. The Generic Drug Approval Process
   C. The Biologics Approval Process

III. Special Innovation Incentives and Disincentives for FDA-Regulated Products
   A. Approval of Duplicates and Variants Based On Innovator Data – ANDAs, “Hybrid” or “505(b)(2)” NDAs, Biosimilars, Follow-on Medical Devices
   B. Infringement Safe Harbor for FDA Submission-Related Acts
   C. Patent Term Extensions
   D. Non-Patent Exclusive Marketing Rights - Orphan Drugs, New Compounds and Uses, Pediatric Studies

IV. Eligibility for Abbreviated NDA Approval
   A. The “Same”-ness Requirement – Active and Inactive Ingredients, Bioavailability, Conditions of Use, and Labeling
   B. Approval Based On Discontinued Innovator Drug

V. The Role of Patents In the FDA Approval Process
   A. The Patent Listing (“Orange Book”) Requirement
   B. The “Paragraph IV” Certification and Notice Requirement
   C. ANDA Filing As An Act of Infringement
   D. The Automatic 30-Month Stay of ANDA Approval
   E. 180-Day Exclusivity For First Paragraph IV Filers
   F. Antitrust Issues in Pharmaceutical Patent Litigation Settlements

VI. The Impact of FDA Regulation On Copyright, Trademark, and Trade Dress Rights
   A. Copyrighted Innovator Labeling and the Generic “Same Labeling” Requirement
   B. Unapproved Products and the “Lawful Use In Commerce” Requirement
   C. Statutory Product Categories and Likelihood of Confusion
   D. FDA Regulation of Trademark Selection
   E. Trade Dress Protection for Drug Product Color, Shape, and Size
   F. Private Remedies Against Marketing Claims for FDA-Regulated Products

VII. The Impact of FDA Regulation on Trade Secrets and Data Confidentiality